These intentionally malicious, and insidious lies are meant

New Post Public Reply Private Reply Replies (3) Message Board
Dr.Acula
1,218
These intentionally malicious, and insidious lies are meant to cause fear, confusion, panic, in order to erode your trust of yourself, and a company that has a therapeutic that works in saving lives.

"Bronstein Gewirts & Grossman" shareholder alerts are utter and complete nonsense, a total sack of lies, along with "Scott + Scott, Kessler Topax Meltzer & Check, Pomerantz Law", the likes blasting across our updates daily in recent reposts of threats of litigation which are simply scare tactics. Words like "insolvency","bankruptcy","investigation", just because Trump said drink Chlorine, it'll kill the virus, doesn't mean you should believe it. Just like that, don't drink these "law offices" Kool Aid either.


They want you to join their class action lawsuit?! Pathetic.They were the ones who pretended to sue CYDY last year in support of the run up to the massive short attack on June 30th 2020. They're the ones who put up a STAT article and then pulled it a few hours after. They're the same ones who tried to campaign in a coordinated attack across multiple sites to destroy CYDY last year, and failed. They're going to fail again this time, because we have ever BETTER data than ever! Oho guess what we have on our side? Science. Science ladies and gentlemen! Science, WILL Prevail.

Fact: NP and SK sold shares in order to make payments to Samsung, they forfeited effectively their own future pay to keep the drug manufacturing running smoothly.

Any sleazeball trying to spin that in ALL of the articles across the internet, all of these years, are all spinning the same deceit and lies, trying to paint a hardworking group of good people as anything but. It's tiresome, and annoying, if you let it bother you.

I watched it happen in real time. Disgusting these "lawyers" and shorts, and now they're trying to get your information to further scare you and basically burn the company because hey guess what, they have a product that works.

Don't fall for it new investors. We longs have seen this before, and we're going to continue to see this.

Didn't one of these firms addresses actually turn out to be some empty parking lot according to google maps? Another turned out to be some other storefront altogether.

Trust the science. Don't even bother reading this sneers and jeers from the sidelines, it's nothing more than playground bullying across the internet.

Next!

Let's refocus on the science here people. The data is the data, and the data shows, Leronlimab WORKS. If you need some more proof, reread Jay's open letter, which he has be advocating for over a year now (pro140 that is):

" March 10, 2021
Dear Dr. Woodcock,
The FDA has protected the American public during Covid by issuing various EUAs, but no treatment has been advanced that specifically helps our most vulnerable citizens-those who are critically ill. And unfortunately, with variant strains now circulating, a potential 4th wave is possible.
CytoDyn’s CD12 trial is the first randomized, double-blind, placebo-controlled study to suggest a striking survival benefit for critically ill Covid patients (24% reduced mortality; p value nss). The study demonstrates statistical significance on a variety of crucial secondary endpoints including shortened hospital stay (6 days; P=0.005), improved survival in patients who received SOC therapy (N=309; P=0.031), and improved survival in patients under 65 years of age, including both all patients under 65 (N=221; P=0.02) and well as those who were critically ill (N=44; P=0.006). The study also demonstrated no safety concerns, consistent with the benign safety profile seen in about 1,000 other HIV+, cancer, and Covid patients who have received leronlimab. The unfortunate imbalance in randomization of patients > 65 years of age (and especially > 75 years) in the CD12 study should not, however, prevent patient access to a potentially life saving medication now while a study of additional critically ill patients is underway. Taken together, the CD12 efficacy signals in critically ill patients combined with the consistently benign safety profile, provide a compelling risk:benefit ratio and ample justification for FDA to issue an EUA for leronlimab for this population now.
I am consulting in the care of a 57 year old man with critical Covid who was on ECMO for 61 days at St. Thomas hospital in London. He received emergency leronlimab on day 79 of his hospitaliztion and starting weaning off ECMO 4 days later. I have attached the case report below, which has been peer reviewed and accepted for publication. Please give it your consideration. Though anecdotal, this case underscores the dramatic recovery that is possible with leronlimab even in the most critically ill patients with Covid.
I have been an independent investigator on about 50 POC studies of novel antiviral agents over the last 31 years (including HIV, CMV, HCV, HBV, HSV, HPV, and Influenza). Also, I have no equity stake in this.
I know leronlimab to be safe and I believe it can help save critically ill patients with Covid-19. Please give these patients and their medical teams a fighting chance.

Respectfully,
Jacob Lalezari, MD Director, Quest Research SF, CA
"




1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 61

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 53

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 58

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 87

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 95

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

Hisense Tech Powers FIFA 2026 VAR Operations in Dallas

Updated Category News Views 101

Hisense Takes Center Stage in FIFA 2026 VAR Operations Let's cut straight to the chase: Hisense isn't just showing up; they're playing a pivotal role in the FIFA World Cup 2026™. The company has woven its way into the fabric of the tournament by becoming the official provider for Video Assistant Referee (VAR) Review TVs. Picture this: At the International Broadcast...

Continue Reading
Consumers Energy's Strategic Energy Savings Transform Schools

Updated Category News Views 329

Significant Energy Savings for Schools Consumers Energy has taken a remarkable step forward in supporting local educational institutions with their energy efficiency initiatives. The utility company has partnered with Grand Rapids Public Schools, one of the most extensive school networks in the state, to implement crucial energy-saving measures. This collaboration has led...

Continue Reading
Enovis Corporation to Showcase Innovations at Investor Events

Updated Category News Views 195

Enovis Corporation's Upcoming Investor Participation Enovis Corporation (NYSE: ENOV) is an innovation-led medical technology company, passionate about delivering solutions that positively affect patient outcomes. The company's management team has exciting updates about their participation in significant investor conferences. Key Conferences On the Horizon On June 10th,...

Continue Reading
Ambassador Linda Thomas-Greenfield Joins Rendeavour's Vision

Updated Category News Views 177

Ambassador Linda Thomas-Greenfield Joins Rendeavour Board TATU CITY, Africa – Rendeavour, a prominent city builder on the continent, has proudly announced the addition of Ambassador Linda Thomas-Greenfield to its board of directors. A dedicated career diplomat, Ambassador Thomas-Greenfield served as the U.S. Ambassador to the United Nations from 2021 to 2025, making...

Continue Reading
Energizer Holdings, Inc. Announces Upcoming Investor Webcast

Updated Category News Views 258

Energizer Holdings, Inc. Hosts Investor Webcast for Q4 Results Energizer Holdings, Inc. (NYSE: ENR) is gearing up to share its financial performance, including the Fourth Quarter and Fiscal Year 2025 results. This will occur prior to the market opening on November 18. The company is excited to communicate the insights from these results during an investor conference call...

Continue Reading